Searchable abstracts of presentations at key conferences in endocrinology

ea0086bpw2.1 | New advances in neuroendocrinology | SFEBES2022

How does the brain know what you’ve eaten?

Garcia-Caceres Cristina

The underlying basis for understanding of how brain control energy homeostasis, resides in a functional and coordinate communicating pathways between peripheral endocrine organs and the brain, in which the hypothalamus plays a pivotal role in the integration and processing of peripheral metabolic cues into satiety and feeding signals. Glial cells in particular astrocytes, as being an integral cell type of the neurovascular unit forming direct physical contacts with cerebral b...

ea0020s11.2 | New aproaches to epigenetics and hormone/gene regulation | ECE2009

Existence of a ‘dormant’ androgen receptor-regulated gene program revealed by ChIP-seq and its influence in prostate cancer progression

Garcia-Bassets Ivan

Prostate cancer (PCa) patients are typically treated by androgen ablation therapies that ultimately fail when PCa enters in androgen-depletion independence (ADI), leading to metastasis and death. To develop better clinical treatments it is crucial to understand the mechanisms underlying progression towards ADI and metastasis. Using ChIP-seq technology, I will show how the forkhead factor FoxA1 precisely restricts the extension of the androgen receptor (AR) binding program main...

ea0056ep10 | Adrenal and Neuroendocrine Tumours | ECE2018

A case of oncocytic adrenocortical neoplasm of borderline malignant potencial

Garcia-Garcia-Doncel Lourdes , Baena-Nieto Gloria , Marquez-Pardo Rosa

Introduction: Oncocytic adrenocortical neoplasms (OAN) are very rare tumors and they are usually nonfunctional and benign. Approximately 17% of the adrenal oncocytomas are functional. Their clinical and pathological characteristics are unique. The estimated overall median survival for malignant OANs is more favorable than that of conventional adrenocortical carcinomas.Case report: We present the case of a 79-year-old male who attended consultations for s...

ea0020p237 | Bone/Calcium | ECE2009

Thin healthy women have a similar low bone mass as women with anorexia nervosa

Fernandez-Garcia Diego , Sebastian Arantzazu , Garcia-Aleman Jorge , Garcia-Almeida Jose Manuel , Tinahones Francisco

Association between anorexia nerviosa (AN) and low bone mass has been demonstrated. Bone loss associated with AN involve hormonal and nutritional impairments, though their exact contribution is not clearly established. We compare bone mass in AN patients with women of similar weight with no criteria for anorexia nervosa, and a third group of healthy, normal-weight, age-matched women. The study included 48 patients with AN (DSM-IV criteria), 22 healthy eumenorrheic women with l...

ea0035p91 | Bone and Osteoporosis | ECE2014

Usefulness of serum sclerostin as a diagnostic marker of osteoporosis in a cohort of spanish postmenopausal women

Luque-Fernandez Ines , Garcia-Martin Antonia , Reyes-Garcia Rebeca , Morales-Santana Sonia , Garcia-Fontana Beatriz , Munoz-Torres Manuel

Introduction: Sclerostin, produced by osteocytes, is a potent inhibitor of Wnt signaling and bone formation. The usefulness of its determination in clinical practice is not well established.Objectives: The aims of this study were to evaluate serum sclerostin levels in a cohort of Spanish posmenopausal women, and to analyze its relationship with bone metabolism.Methods: We measured serum sclerostin in 97 posmenopausal women using EL...

ea0029p1670 | Thyroid (non-cancer) | ICEECE2012

Iodine supply and prevalence of thyroid autoimmunity and autoimmune thyroiditis in children and adolescents between 1 and 16 years old in our city

Garcia-Garcia E. , Vazquez-Lopez M. , Garcia-Fuentes E. , Rodriguez-Sanchez F. , Munoz-Vico J. , Bonillo A. , Soriguer F.

Introduction: Thyroid autoimmunity is related to iodine supply. Iodine nutrition has improved in our country, but the prevalence of autoimmune thyroiditis in our children is unknown.Objectives: To determine the status of iodine nutrition in children and adolescents in our city. To calculate local prevalence of thyroid autoimmunity and autoimmune thyroiditis in pediatric ages.Design: Cross-sectional epidemiological study.<p clas...

ea0081ep817 | Pituitary and Neuroendocrinology | ECE2022

Pituitary Stalk Interruption Syndrome in a 22-year old Filipino Male : A case report

Kei Bariuad-Garcia Irene , Paz Cecille Dela

Background: Pituitary Stalk Interruption Syndrome (PSIS) is a rare congenital anomaly affecting the pituitary gland with characteristic MRI findings of small or absent anterior pituitary gland, misplaced or absent posterior pituitary gland and very thin or interrupted pituitary stalk (1). Patients with PSIS often presents with signs and symptoms of either isolated growth hormone deficiency or multiple anterior pituitary hormone deficiency and symptoms differ according to age a...

ea0090p807 | Late-Breaking | ECE2023

Retinal quantitative traits as prognostic factors for diabetic cardiomyopathy in people with type 2 diabetes: A scoping review

Sandoval Garcia Emmanuel , Stephani Hellwege Rubi

Introduction: Heart failure (HF) morbidity and mortality are increasing at an alarming rate in people with type 2 diabetes (T2D). Myocardial dysfunction may develop without ischemic heart disease (IHD), hypertension, or valvular pathologies, and which is defined as diabetic cardiomyopathy (DCM). Although the pathophysiology of DCM is unclear, DCM is initially characterised by myocardial fibrosis, dysfunctional remodelling, and associated diastolic dysfunction, later by systoli...

ea0090ep589 | Endocrine-related Cancer | ECE2023

Alpelisib-induced severe hyperglycemia: A case report. Are we discontinuing the drug too soon?

Garcia Fernandez Javier , Perera Izquierdo Marcos

Background: Alpelisib is an α-selective PI3K inhibitor indicated for the treatment of postmenopausal women and men with hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2–), PIK3CA-mutated locally advanced or metastatic breast cancer following disease progression or after endocrine therapy. Hyperglycemia is the most common adverse event (up to 60%) associated with its use. It occurs more frequently and lasts longer in patients with pred...